VectivBio Holding AG

Ladies and gentlemen, thank you for standing by. Welcome to Vectiv's BIOS conference call to report full year 2021 financial results. My name is Livia, and I'll be your conference operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will fall at that time. As a reminder, this call is being recorded at Vectiv BIOS request. Now, I would like to introduce your host for today's call, Claudia D'Acosta, Chief Financial Officer, please go ahead.

Thank you and good morning, everyone. Welcome to today's call during which we will provide an update on the company and review our financial results for the full year ended December 31st, 2021. Earlier this morning, we issued a press release summarizing our financial results and progress across the company, which is available on our website. I would like to remind everyone that today's discussion will include statements about our future expectations, plans, and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the risk factors discussed in our SSE filings, and we are not under any obligation to update any forward-looking statements. Joining me today here in Basel are Luca Santarelli, Chief Executive Officer, and Omar Kwaja, our Chief Medical Officer. We estimate that our remarks will take about 20 minutes Then we will open up to Q&A, at which point we will be joined by Kevin Harris, our Chief Commercial Officer, who is based in the U.S. Now I'd like to turn the call over to Luca.

Thank you, Claudia, and thanks to everyone for joining us today.